Steiner Margaret, Frank Jacklyn, Saenger Paul
NYU Langone Health-Long Island 101 Mineola Boulevard Mineola New York USA.
Pediatr Investig. 2023 Jan 3;7(1):36-42. doi: 10.1002/ped4.12358. eCollection 2023 Mar.
After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the only drug available for the treatment of GH deficiency. In 1985, recombinant GH became available, and the modalities of GH therapies changed dramatically as the supply was unlimited. New indications for GH in pediatrics and adult medicine were developed. Treatment was daily. Now in 2021 long-acting GH (LAGH) became available the world over making GH therapy more patient-friendly and even showing slightly greater efficacy than daily GH therapy. We are now entering a new era of LAGH therapy for pediatric and adult use with new formulations of GH, which will predictably be the preferred form of GH therapy for years to come increasing adherence to GH therapy and possibly even efficacy, that is, better growth rate. The continued availability of new safety data will further solidify the use of LAGH in clinical medicine.
1957年垂体生长激素（GH）分离出来后，这种总是供应有限的GH形式，是治疗GH缺乏症的唯一可用药物。1985年，重组GH问世，随着供应不受限制，GH治疗方式发生了巨大变化。儿科和成人医学中GH的新适应症得以开发。治疗是每日进行的。如今在2021年，长效GH（LAGH）在全球范围内上市，使GH治疗对患者更友好，甚至显示出比每日GH治疗略高的疗效。我们现在正进入一个LAGH治疗的新时代，用于儿科和成人，有新的GH制剂，预计在未来几年它将成为GH治疗的首选形式，提高对GH治疗的依从性，甚至可能提高疗效，即更好的生长速度。新的安全性数据的持续可得性将进一步巩固LAGH在临床医学中的应用。
